# Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler

> **NCT02416180** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 111 (actual)

## Conditions studied

- Asthma

## Interventions

- **DEVICE:** SERETIDE MDI
- **DEVICE:** Placebo DISKUS Inhaler
- **DEVICE:** Placebo MDI

## Key facts

- **NCT ID:** NCT02416180
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-18
- **Primary completion:** 2015-08-20
- **Final completion:** 2015-08-20
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02416180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02416180, "Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02416180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*